Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 6;10(1):101670.
doi: 10.1016/j.adro.2024.101670. eCollection 2025 Jan.

Outcomes and Toxicities After Treatment for Men Diagnosed With Localized Prostate Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis

Doris Kitson-Mills  1 , Andrew Donkor  1   2 , Yaw Ampem Amoako  3 , Kofi Adesi Kyei  4 , Ernest Barwuah Osei Bonsu  5 , Verna Vanderpuye  6 , Yaw Amo Wiafe  1
Affiliations
Review

Outcomes and Toxicities After Treatment for Men Diagnosed With Localized Prostate Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis

Doris Kitson-Mills et al. Adv Radiat Oncol. .

Abstract

Purpose: Current management for clinically localized prostate cancer in low- and middle-income countries (LMICs) includes surgery, external beam radiation therapy (EBRT), and brachytherapy either alone or in combination, with plus or minus hormone therapy. The toxicity profiles and oncological outcomes of these treatment modalities vary. This systematic review and meta-analysis aimed to determine the prevalence of treatment-related outcomes and toxicities for men diagnosed with localized prostate cancer in LMICs.

Methods and materials: The review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Cochrane Library, Embase, and Medline were searched for eligible articles. Meta-analysis was performed with Review Manager version 5.4.1 using a random effects model at a 95% confidence interval.

Results: A total of 2,820 patients were analyzed from 24 articles that met the inclusion criteria. Following 3-dimensional conformal radiation therapy (3D-CRT), the most common clinician-reported toxicities were acute skin grade 1, acute genitourinary grade 1, acute gastrointestinal grade 1, and late gastrointestinal grade 1, with 46%, 29%, 24%, and 18%, respectively. Acute and late genitourinary grade 3 and gastrointestinal grade 3 toxicities were below 3% with no grade 4 toxicities reported after 3D-CRT. In the brachytherapy group, the prevalence of acute genitourinary grade 1 toxicity was 19%. Perioperative rectal injury was the least prevalent (2%) after retropubic radical prostatectomy. Following 3D-CRT, the 5-year overall survival rate was 87%, and for the combined brachytherapy and EBRT group, it increased to 96%. The prevalence of 5-year biochemical failure following EBRT and brachytherapy was 18% and 30%, respectively. The 4- and 3-year biochemical failure after radical prostatectomy and combined EBRT with brachytherapy were 22% and 2%, respectively.

Conclusions: This systematic review and meta-analysis indicate that in LMICs, EBRT, brachytherapy, and radical prostatectomy, either alone or in combination has an excellent potential for localized prostate cancer control with low toxicities and good oncological outcomes. Results of treatment-related toxicities and outcomes can support policymakers, patients, and clinicians on informed decision-making to strengthen prostate cancer care in the region. However, efforts are required to improve early detection, treatment accessibility, regular post-treatment follow-up care, consistent quality assurance practices, and staff continues development to help minimize treatment toxicities and improve outcomes of localized prostate cancer in LMICs.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Geographic distribution of included studies.
Figure 3
Figure 3
Forest plot for the prevalence of acute skin toxicity after 3-dimensional conformal radiation therapy.
Figure 4
Figure 4
Forest plot for the prevalence of biochemical failure following radiation therapy.
Figure 5
Figure 5
Forest plot for the prevalence of 5-year overall survival following radiation therapy.
Figure 6
Figure 6
Forest plot for the prevalence of cause of death other than prostate cancer following radiation therapy.
Figure 7
Figure 7
Forest plot for prevalence of acute genitourinary toxicity following brachytherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. James ND, Tannock I, N'Dow J, et al. The Lancet Commission on prostate cancer: Planning for the surge in cases. Lancet. 2024;403:1683–1722. - PMC - PubMed
    1. Hack B, Piddock K, Stanway S, et al. Cancer control in low-and middle-income countries: Time for action. J R Soc Med. 2019;112:213–217. - PMC - PubMed
    1. Cassell A, Yunusa B, Jalloh M, et al. A review of localized prostate cancer: An African perspective. World J Oncol. 2019;10:162–168. - PMC - PubMed
    1. Kavuma A, Kibudde S, Schmidt M, et al. Remote global radiation oncology education and training: A pathway to increase access to high-quality radiation therapy services in low-and middle-income countries. Adv Radiat Oncol. 2023;8 - PMC - PubMed

LinkOut - more resources